H.C. Wainwright lowered the firm’s price target on Belite Bio (BLTE) to $98 from $100 and keeps a Buy rating on the shares. The firm cites higher shares outstanding post the equity financing for the target cut.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Promising Outlook for Belite Bio, Inc. Amidst Phase 3 Success and Strong Financial Position
- Belite Bio completes Phase 3 DRAGON trial of Tinlarebant
- Belite Bio announces up to $250M upsized private placement financing
- Belite Bio Secures $125 Million in PIPE Financing with Potential for More
- Promising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio